Shots:

• Boston Scientific has signed a definitive agreement to acquire Silk Road Medical for $27.50 per share, making it an aggregate of ~$1.16B. The transaction will conclude in H2’24, contingent upon customary closing conditions
• The acquisition adds Silk Road Medical’s transcarotid artery revascularization (TCAR) technology, intended to prevent stroke & treat carotid artery disease, to the company’s vascular portfolio
• The TCAR procedure reverses the blood flow by accessing the carotid artery via a small neck incision to prevent plaque from dislodging. A stent is then positioned to stabilize plaque, preventing future strokes

Ref: Boston Scientific | Image: Boston Scientific

Related News:- Boston Scientific Corporation Highlights 6 Months Data of MODULAR ATP Study & 5 Years Data of APPRAISE ATP Study at Heart Rhythm 2024

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com